Canadian Hash market provides potentially large, emerging opportunity for Mernova▪ Legal Hash market is currently under-supplied and lacks high-quality products despite significant demand▪ Mernova to diversify product range in the coming year with launch of new products expected in Q1 2021▪ Mernova facility infrastructure has ability to support this new arm of the business▪ Feedback from end users and resellers is that initial orders will occur immediatelyupon launch into HashCreso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise its wholly-owned Canadian subsidiary, Mernova Medicinal Inc. (“Mernova”) has made the strategic decision to expand its current operations and target the Canadian Hash (“Hashish”) market.The decision follows a comprehensive review of the significant market opportunities available across Canada, and very positive customer feedback regarding Mernova’s current product range.On October 17, 2019, Cannabis 2.0 legalized the production and sale of edible cannabis, cannabis extracts and cannabis topicals. Hash, a chemical-free, solventless extract produced by physically separating and collecting trichomes from cannabis flowers and applying heat and pressure, can now be legally produced and sold in Canada. It has the ability to improve and appreciate, with age, and if properly stored, can be kept for up to 12 years or longer. Being a concentrate, it has higher cannabinol content than the starting material.Pictured above: Hash products produced at Mernova’s Nova Scotia Facility.
CPH Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
